BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...
BioCentury | Jun 2, 2020

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II...
BioCentury | Jan 11, 2020
Company News

Chinook to spin AbbVie castoff into personalized kidney disease candidate

The trend towards personalized medicine for renal diseases continues with Chinook’s licensing of atrasentan from AbbVie. The biotech plans to put its precision medicine spin on the endothelin A receptor while transitioning it from the...
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...
BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

With plans to discontinue fosmetpantotenate after its Phase III miss, Retrophin President and CEO Eric Dube believes the $425 million with which it ended last quarter is enough to bring its remaining clinical candidate to...
BioCentury | May 15, 2019

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the...
BioCentury | Apr 10, 2019
Company News

Gilead cuts cardiopulmonary sales reps

Gilead said it will lay off about 150 cardiopulmonary sales representatives due to the anticipated market entry of generic versions of Letairis ambrisentan and Ranexa ranolazine. The decision was put into motion almost two years...
BioCentury | Mar 22, 2019
Clinical News

Opsumit improves right ventricular function in PAH patients

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension. The...
BioCentury | Jul 13, 2018
Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised on July 11 CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of...
Items per page:
1 - 10 of 797